Identification

Name
Magnesium salicylate
Accession Number
DB01397
Type
Small Molecule
Groups
Approved
Description

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.

It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects.

Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.

Structure
Thumb
Synonyms
  • Magnesium salicylate anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Magnesium salicylate tetrahydrate41728CY7UX18917-95-8CWQGWAKCTBFURY-UHFFFAOYSA-J
Active Moieties
NameKindUNIICASInChI Key
Salicylic acidunknownO414PZ4LPZ69-72-7YGSDEFSMJLZEOE-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arthriten TabletsTablet325 mgOralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Back-ese M Tab 325mgTablet325 mgOralG.T. Fulford Pharmaceuticals1985-12-311998-06-25Canada
Back-ese M Tablets 325 mgTablet325 mgOralDannorth Laboratories Inc.1980-12-312000-07-19Canada
Backache AidTablet, film coated580 mg/1OralL&R Distributors, Inc.1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralRite Aid1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralCVS Health1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet, film coated580 mg/1OralLnk International, Inc.1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet580 mg/1OralWalgreen1998-11-072018-04-10Us
Doan's Backache Pills 325mgTablet325 mgOralNovartis1988-12-311998-07-08Canada
Doans Extra StrengthTablet580 mg/1OralDr Reddy's Laboratories2016-05-24Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Arthriten Joint Pain ReliefMagnesium salicylate tetrahydrate (310 mg/1) + Acetaminophen (250 mg/1) + Caffeine (32.5 mg/1)Tablet, film coatedOralAlva-Amco Pharmacal Companies, Inc.2002-10-282010-05-17Us
Back ReliefMagnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)TabletOralHoneywell Safety Products USA, Inc2013-05-142017-12-20Us
Back ReliefMagnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)TabletOralHoneywell Safety Products USA, Inc2017-12-20Not applicableUs
Diurex Water PillsMagnesium salicylate tetrahydrate (162.5 mg/1) + Caffeine (50 mg/1)Tablet, coatedOralAlva Amco Pharmacal Companies, Inc.2005-05-15Not applicableUs
MEDIQUE Back Pain OffMagnesium salicylate tetrahydrate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1)Tablet, film coatedOralUnifirst First Aid2008-12-30Not applicableUs
Otis Clapp Back QuellMagnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)Tablet, film coatedOralUnifirst First Aid2008-12-30Not applicableUs
Pain Aid BRFMagnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1)TabletOralZee Medical Inc2012-08-19Not applicableUs
Pamprin Cramp Menstrual Pain ReliefMagnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1) + Pamabrom (25 mg/1)TabletOralChattem, Inc.1983-01-01Not applicableUs
Trilisate TabMagnesium salicylate (362 mg) + Choline salicylate (293 mg)TabletOralPurdue Pharma1979-12-312002-07-30Canada
Vica-cetMagnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1)TabletOralProvision Medical2015-04-03Not applicableUs
Categories
UNII
JQ69D454N1
CAS number
18917-89-0
Weight
Average: 298.531
Monoisotopic: 298.03277995
Chemical Formula
C14H10MgO6
InChI Key
MQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2-hydroxybenzoate)
SMILES
[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain

Pharmacodynamics
Not Available
Mechanism of action

Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Magnesium Salicylate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Magnesium salicylate.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.
5-androstenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 5-androstenedione.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Abciximab.
AcebutololMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acemetacin.
AcenocoumarolMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenMagnesium salicylate may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Food Interactions
Not Available

References

Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.

US5043168
General References
Not Available
External Links
Human Metabolome Database
HMDB0015469
KEGG Compound
C07995
PubChem Compound
54684589
PubChem Substance
46508713
ChemSpider
58278
ChEBI
6640
ChEMBL
CHEMBL2106755
PharmGKB
PA450300
Wikipedia
Magnesium_salicylate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Caraco Pharmaceutical Labs
  • CVS Pharmacy
  • Ivax Pharmaceuticals
  • Key Co.
  • Novartis AG
  • Palmetto Pharmaceuticals Inc.
  • Qualitest
  • US Pharmaceutical Corp.
Dosage forms
FormRouteStrength
TabletOral325 mg
TabletOral580 mg/1
Tablet, film coatedOral580 mg/1
Tablet, coatedOral
CapsuleOral580 mg/1
TabletOral650 mg
Tablet, film coatedOral
Tablet, coatedOral467 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Tricosal 1000 mg tablet1.23USD tablet
Choline mag trisal 1 gm tablet1.15USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Novasal 600 mg tablet0.75USD tablet
Choline mag trisal 500 mg tablet0.64USD tablet
Doan's ex strength 580 mg tablet0.22USD tablet
CVS Pharmacy backache rlf 580 mg caplet0.18USD caplet
Doan's regular 325 mg tablet0.18USD tablet
Keygesic-10 650 mg tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0686 mg/mLALOGPS
logP2.86ALOGPS
logP1.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5741
Blood Brain Barrier+0.829
Caco-2 permeable+0.5941
P-glycoprotein substrateNon-substrate0.6758
P-glycoprotein inhibitor INon-inhibitor0.9704
P-glycoprotein inhibitor IINon-inhibitor0.9768
Renal organic cation transporterNon-inhibitor0.8975
CYP450 2C9 substrateNon-substrate0.7872
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateNon-substrate0.7282
CYP450 1A2 substrateNon-inhibitor0.8837
CYP450 2C9 inhibitorNon-inhibitor0.5705
CYP450 2D6 inhibitorNon-inhibitor0.9113
CYP450 2C19 inhibitorNon-inhibitor0.8537
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9021
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8587
BiodegradationReady biodegradable0.8277
Rat acute toxicity2.3552 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.9555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts
show 2 more
Substituents
Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid
show 7 more
Molecular Framework
Not Available
External Descriptors
benzenes, carbonyl compound (CHEBI:6640)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441]

Drug created on July 08, 2007 11:04 / Updated on October 01, 2018 16:44